New Gene-Silencing shot aims to lower bad cholesterol
NCT ID NCT07428473
First seen Feb 23, 2026 · Last updated May 05, 2026 · Updated 8 times
Summary
This early-phase study tests a new drug called STX-1150 that aims to lower 'bad' LDL cholesterol by temporarily silencing a gene in the liver. About 64 adults with high cholesterol will receive one or more doses and be followed for up to a year. The main goal is to check safety and how well the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ELEVATED LDL-C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Monash Health/ Victorian Heart Hospital (VHH)
Clayton, Victoria, 3168, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.